Perspective Therapeutics, Inc.
CATX
$3.00
$0.072.39%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 76.00K | 43.00K | 209.00K | 290.00K | 342.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.00K | 43.00K | 209.00K | 290.00K | 342.00K |
| Cost of Revenue | 21.37M | 32.92M | 20.34M | 16.62M | 14.33M |
| Gross Profit | -21.30M | -32.88M | -20.13M | -16.33M | -13.99M |
| SG&A Expenses | 6.99M | 6.95M | 7.73M | 7.71M | 7.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.36M | 39.88M | 28.07M | 24.33M | 22.17M |
| Operating Income | -28.28M | -39.83M | -27.86M | -24.04M | -21.83M |
| Income Before Tax | -26.19M | -38.28M | -25.97M | -22.00M | -18.18M |
| Income Tax Expenses | -- | -793.00K | -- | -- | -- |
| Earnings from Continuing Operations | -26.19M | -37.49M | -25.97M | -22.00M | -18.18M |
| Earnings from Discontinued Operations | -- | 0.00 | -- | 514.00K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.19M | -37.49M | -25.97M | -21.49M | -18.18M |
| EBIT | -28.28M | -39.83M | -27.86M | -24.04M | -21.83M |
| EBITDA | -27.16M | -38.83M | -27.09M | -23.31M | -21.10M |
| EPS Basic | -0.25 | -0.50 | -0.35 | -0.29 | -0.25 |
| Normalized Basic EPS | -0.16 | -0.32 | -0.22 | -0.19 | -0.16 |
| EPS Diluted | -0.25 | -0.50 | -0.35 | -0.29 | -0.25 |
| Normalized Diluted EPS | -0.16 | -0.32 | -0.22 | -0.19 | -0.16 |
| Average Basic Shares Outstanding | 103.60M | 74.34M | 74.30M | 74.24M | 72.36M |
| Average Diluted Shares Outstanding | 103.60M | 74.34M | 74.30M | 74.24M | 72.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |